4.875
0.41%
-0.025
전일 마감가:
$4.90
열려 있는:
$4.91
하루 거래량:
198.60K
Relative Volume:
0.33
시가총액:
$284.92M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
18.06
EPS:
0.27
순현금흐름:
$12.42M
1주 성능:
-4.31%
1개월 성능:
+3.17%
6개월 성능:
-4.50%
1년 성능:
+41.45%
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
VNDA | 4.88 | 284.92M | 192.64M | 2.51M | 12.42M | 0.27 |
VRTX | 449.86 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.01 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.88 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 107.22 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
2021-05-12 | 개시 | BofA Securities | Buy |
2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2018-12-04 | 재확인 | Jefferies | Buy |
2018-11-08 | 재개 | Jefferies | Buy |
2018-09-21 | 재개 | Oppenheimer | Outperform |
2018-05-23 | 개시 | Citigroup | Buy |
2018-01-19 | 개시 | Seaport Global Securities | Buy |
2017-09-14 | 재확인 | Piper Jaffray | Overweight |
2017-06-27 | 재개 | Piper Jaffray | Overweight |
2017-05-26 | 개시 | H.C. Wainwright | Buy |
2017-04-12 | 개시 | Oppenheimer | Outperform |
2016-11-09 | 개시 | Aegis Capital | Buy |
2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Long Term Trading Analysis for (VNDA) - Stock Traders Daily
Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India
Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
New Strong Buy Stocks For November 14th - Barchart
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria
Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan
BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz
Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review
Vanda: Q3 Earnings Snapshot - Middletown Press
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat
Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN
Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance
Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance
Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance
D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters
Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):